These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 3876272)
1. Effector mechanisms of syngeneic anti-tumour responses in mice. II. Cytotoxic T lymphocytes mediate neutralization and rejection of radiation-induced leukaemia RL male 1 in the nude mouse system. Keyaki A; Kuribayashi K; Sakaguchi S; Masuda T; Yamashita J; Handa H; Nakayama E Immunology; 1985 Sep; 56(1):141-51. PubMed ID: 3876272 [TBL] [Abstract][Full Text] [Related]
2. Effector mechanisms of syngeneic anti-tumour responses in mice. I. Establishment and characterization of an exogenous IL-2-independent cytotoxic T-lymphocyte line specific for radiation-induced leukaemia RL male 1. Kuribayashi K; Keyaki A; Sakaguchi S; Masuda T Immunology; 1985 Sep; 56(1):127-40. PubMed ID: 3876271 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice. Fuyama S; Yamamoto H; Fujii Y; Arai S Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480 [TBL] [Abstract][Full Text] [Related]
4. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape. Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255 [TBL] [Abstract][Full Text] [Related]
5. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level. Sensi M; Orosz CG; Bach FH J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778 [TBL] [Abstract][Full Text] [Related]
6. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones. Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090 [TBL] [Abstract][Full Text] [Related]
7. Leukemic cells arise from cloned cytotoxic lymphocytes during cell culture. Simon MM; Ali S; Tewari R; Simon HG; Müller-Hermelink HK; Epplen JT Eur J Immunol; 1986 Oct; 16(10):1269-76. PubMed ID: 3095125 [TBL] [Abstract][Full Text] [Related]
8. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice. Yoshimura A; Shiku H; Nakayama E J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592 [TBL] [Abstract][Full Text] [Related]
9. Cell-mediated immune responses to syngeneic ultraviolet-induced tumours. V. Assessment of accessory and antigen-presenting cell capabilities of normal and ultraviolet-irradiated mice in the generation of anti-tumour cytotoxic effector cells in vitro. Lynch DH; Gurish MF; Daynes RA Immunology; 1982 Sep; 47(1):49-59. PubMed ID: 6981587 [TBL] [Abstract][Full Text] [Related]
10. Relationships among differentiated T-cell subpopulations. V. T-cell dependent mechanism of xenograft rejection and its radioresistant nature. Terasaka R; Nomoto K; Himeno K Immunology; 1979 Dec; 38(4):773-9. PubMed ID: 316419 [TBL] [Abstract][Full Text] [Related]
11. [Effects of TCGF (T-cell growth factor) on experimental malignant glioma-specific killer T-cell]. Yamasaki T; Yamashita J; Handa H; Namba Y; Hanaoka M No Shinkei Geka; 1984 Feb; 12(2):141-50. PubMed ID: 6609319 [TBL] [Abstract][Full Text] [Related]
12. Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas. Yamasaki T; Handa H; Yamashita J; Watanabe Y; Namba Y; Hanaoka M Cancer Res; 1984 May; 44(5):1776-83. PubMed ID: 6608988 [TBL] [Abstract][Full Text] [Related]
13. Neutralization of interleukin-2 retards the growth of mouse renal cancer. Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731 [TBL] [Abstract][Full Text] [Related]
14. Detection of a unique antigen on radiation leukemia virus-induced leukemia B6RV2. Nakayama E; Uenaka A; Stockert E; Obata Y Cancer Res; 1984 Nov; 44(11):5138-44. PubMed ID: 6091870 [TBL] [Abstract][Full Text] [Related]
15. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. Manki A; Ono T; Uenaka A; Seino Y; Nakayama E Cancer Res; 1998 May; 58(9):1960-4. PubMed ID: 9581839 [TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor effect of lymphokine-activated rodent polymorphonuclear leukocytes. Fujii Y; Kimura S; Arai S; Sendo F Cancer Res; 1987 Nov; 47(22):6000-5. PubMed ID: 3117360 [TBL] [Abstract][Full Text] [Related]
17. Functional clonal deletion and suppression as complementary mechanisms operative in adult hapten-induced cytotoxic T cell tolerance. Good MF; Nossal GJ J Immunol; 1983 Dec; 131(6):2662-9. PubMed ID: 6227660 [TBL] [Abstract][Full Text] [Related]
18. Characterization of interleukin 2-dependent cytotoxic T-cell clones: specificity, cell surface phenotype, and susceptibility to blocking by Lyt antisera. Palladino MA; Obata Y; Stockert E; Oettgen HF Cancer Res; 1983 Feb; 43(2):572-6. PubMed ID: 6600215 [TBL] [Abstract][Full Text] [Related]
19. Partially restorative role of T cells for low interleukin 2 dependent growth of NK cell progenitors from nude mice. Riccardi C; Migliorati G; Herberman RB Nat Immun Cell Growth Regul; 1983-1984; 3(1):7-21. PubMed ID: 6235449 [TBL] [Abstract][Full Text] [Related]
20. T cell responses induced by the parenteral injection of antigen-modified syngeneic cells. I. Induction, characterization, and regulation of antigen-specific T helper cells involved in delayed-type hypersensitivity responses. Miller SD; Butler LD J Immunol; 1983 Jul; 131(1):77-85. PubMed ID: 6190929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]